HepCBC Mission Statement

HepCBC is a non-profit organization run by and for people infected and affected by hepatitis C. Our mission is to provide education, prevention and support to those living with HCV.

hepc.bull May 2016 Now Online!

May is National Aboriginal
Hepatitis C Awareness Month

Hot Off The Press!

Tainted Blood Compensation Fund Update – ACTION Requested!

May 2016 Hepatitis C Update – ACTION REQUESTED! As many of you know, the Past Economic Loss and Dependent (PELD) fund of the Pre/Post Hepatitis C Settlement is in a deficit situation – with more than $65 million in unpaid claims.  More than 300 victims are waiting for much needed funds that were promised – and there are likely many more, as the claim assessment process has been halted. At the same time, the 1986-1990 settlement has a surplus of...

Governments on track to eliminate viral hepatitis by 2030

194 Member States commit to eliminating viral hepatitis at World Health Assembly On 28 May, 194 Member States made a historic commitment to eliminate viral hepatitis by 2030. At the 69th World Health Assembly, governments unanimously voted to adopt the first ever Global Viral Hepatitis Strategy, signalling the greatest global commitment in viral hepatitis to date. The Strategy sets a goal of eliminating hepatit...

Washington state told to lift restrictions on hepatitis C medicines

The Washington state Medicaid program has been ordered to lift restrictions on coverage of pricey hepatitis C treatments, according to a preliminary injunction issued Friday by a federal judge in Seattle. The ruling came in response to a lawsuit filed by state residents who claim the drugs are “medically necessary,” and that the decision by the Washington State Health Care Authority to provide coverage to only the sickest patients had caused them harm. I

Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of ZEPATIER™ (elbasvir and grazoprevir), an investigational, once-daily, fixed-dose combination tablet for the treatment of chronic hepatitis C virus (HCV) in adult patients...